Isomorphic Labs
Isomorphic Labs raises $600M Series B at $3.5B valuation
Isomorphic Labs: Series B Funding Round
Isomorphic Labs has successfully raised $600M in Series B funding, reaching a valuation of $3.5B.
Company Overview
AI-powered drug discovery platform applying machine learning to molecular design
Funding Details
The Series B round was led by Alphabet, with participation from Andreessen Horowitz.
Company Information
- Headquarters: London, UK
- Founded: 2021
- Employees: 150+
- Category: Biotech
Investment
Isomorphic Labs plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Alphabet: Verified investor in Series B
- Andreessen Horowitz: Verified investor in Series B
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free